Loading clinical trials...
Loading clinical trials...
A Phase 1b Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Clinically Stable Patients With Ornithine Transcarbamylase Deficiency
Conditions
Interventions
ARCT-810
Placebo
Locations
8
United States
University of Florida
Gainesville, Florida, United States
M Health Fairview Masonic Children's Hospital
Minneapolis, Minnesota, United States
The Mount Sinai Hospital
New York, New York, United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
Baylor University
Waco, Texas, United States
Start Date
November 3, 2020
Primary Completion Date
August 30, 2023
Completion Date
April 30, 2024
Last Updated
August 2, 2024
NCT06805695
NCT05526066
NCT01569568
NCT05910151
NCT00472732
NCT00004498
Lead Sponsor
Arcturus Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions